eligibility_summary
Include: Adults (≥18) with R/R multiple myeloma after ≥3 prior lines (PI, anti‑CD38, anti‑BCMA), measurable disease, ECOG ≤1, adequate renal/hepatic/resp/cardiac function (CrCl/GFR ≥50, ALT ≤5×ULN, bili ≤2×ULN, O2>91%, LVEF ≥45%), contraception 12 months, consent. Exclude: MM therapy <14 d, cellular therapy <8 wk, other trials, severe allergy, prior grade 3 CRS/ICANS, active HBV/HCV/HIV/infection, serious comorbidity, pregnancy/breastfeeding, other malignancy unless cured >2 y. neg preg test.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 trial testing WS-CART-CS1, an autologous CAR-T cell therapy engineered to recognize CS1 (SLAMF7) on multiple myeloma cells, activating T-cell cytotoxicity to kill CS1+ malignant plasma cells. Patients receive lymphodepleting chemotherapy (cyclophosphamide, a DNA-alkylating agent, fludarabine, a purine analog) to suppress host lymphocytes and improve CAR-T expansion/persistence. Targets: CS1/SLAMF7 on myeloma (a SLAM family receptor highly expressed in MM). Pathways/cells affected: CAR-T activation and cytolysis of CS1+ plasma cells, transient depletion of host lymphocytes (including T/NK) by conditioning.